18th International EBHC Symposium 2023
Integrating evidence for enhanced outcomes
9-10 października 2023 | stacjonarnie + ONLINE
Ever since the era of health technologies began, the process of generating scientific evidence has been dispersed, lengthy and divided into stages implemented independently by numerous teams. Initially, research design was too focused on optimising the scope of the collected data, as excessive data volumes could exceed a facility's capacities and its budget. It was necessary for researchers to consider costs (e.g., of analysts’ work), time (required calculations), technical limitations (database capacity) and silo mentality regarding research processes.
Integration no. 1 – uniform questionnaire formats
During the individual stages of the research process, data were formatted and processed to meet the requirements of various methods of analysis and inference. Significant technical, financial, and human resources were engaged in collecting, reproducing, sending, and storing paper and later electronic research documentation. Data gathered with such effort were (and still are) closely guarded by various institutions. Creating and protecting sensitive data is important not only from the perspective of the average patient, but also due to the matter of intellectual property. In the meantime...
Integration no. 2 – scale, assessment, credibility...
Conducting isolated studies, even those large-scale ones, is impractical in the long run, as it does not allow for reaching synergy by combining results from numerous examined populations. Secondary research offered the opportunity to create more accurate conclusions, but it required a standardisation of analytical processes including methods of data synthesis for scientific goals, creating new technologies, as well as analysing healthcare systems.
Integration no. 2.5 – reimbursement!
Another revolution was brought about by applying scientific evidence to assessments of the validity of reimbursing health technologies. The progress of medicine, supported by the pharmaceutical industry (and its primary and secondary research) and, to varying degrees, by the public sector resulted in an enormous growth of knowledge resources, as well as difficulties in implementing them in health care and improving the quality of patient care. The subjective needs of patients were quantified in health technology assessment or quality assessment processes more and more often; however, the adopted tools would not provide an answer to the questions regarding satisfying the needs of people covered by healthcare. top
Integration no. 3 – human factor
New concepts emerged as a counterweight for these imperfections; they were supposed to complete and support HTA-based decision-making and health care management. They include, among others, Value-Based Health Care (VBHC), which focuses on patients’ needs, and Real-World Evidence (RWE). The need to include patients, who are the broadest group of stakeholders begins to take shape in provisions and regulations concerning patients’ participation in the decision-making processes (e.g., NICE's Public Involvement programme). RWE proposes using mass real-world data already at the lowest decision-making processes (e.g., by physicians), bypassing the time-consuming processing and formal reports drawn up by institutions. The COVID-19 pandemic and development of digitalisation accelerated the use of RWE. At the same time, it was the catalyst which boosted the process of creating RWE. Doctors fighting with the pandemic were updating the entire world on an ongoing basis about the results of their activities. That was the first mass use of RWE – without a formal system and with the use of improvised measures (social media, phones, emails).
As technology progresses, especially the ubiquity of digitalisation and a huge increase of database possibilities, it is easier for the contemporary researchers to process data. They do not need to be afraid of the abundance of data. Gathering different types of data resembles playing with blocks which have different types of connection combinations. The more connections our blocks have, the larger the possibility of attaching them to the “structures” (research) of other researchers. However, as the blocks get larger, we need increasingly bigger boxes to store them (databases). In return, we get the possibility to integrate scientific evidence acquired from completely different sources, environments, and research techniques. Creating new connections become the subject of international regulations e.g., of the European Health Data Space (EHDS). top
Integration no. 4 – just new toys or already a matrix?
Integrating scientific evidence at the HTA level becomes increasingly popular and is often initiated at very early stages of creating health technologies. An approach combining randomised controlled trials (RCT) and real-world evidence can serve as a strategic path for growth for all stakeholders of the healthcare system. These new possibilities will also bring about new challenges, not only in the context of medical advances, but also in the evolution of healthcare systems.
The sudden growth of the amount of collected data might give raise to concerns whether their reasonable analysis is possible, but in fact the answer might lie in the implementation of artificial intelligence (AI). Perhaps AI will soon allow us to determine the key models for analysing data and assessing efficacy, e.g., without the need to conduct randomised controlled trials (RCT). It will surely help choose patients for such trials more accurately. Thanks to the RWE analysis with the AI support, it might be possible to create a digital model of the healthcare system that will facilitate following diagnostic paths, monitoring areas that require interventions, identifying, and breaking though diagnostic barriers. Such a model could also adjust the manufacture levels to the system's current needs or recommend the optimal number of places at medical universities based on the trend analysis.
Digitalisation creates such huge opportunities that finding and implementing reasonable ideas to their full potential will still need to take some time. However, new dilemmas are already emerging, such as issues regarding privacy and safety of citizens’ data and the necessity to create solutions that do not generate further inequalities in healthcare.
I o tym wszystkim dyskutowaliśmy na 18. Międzynarodowym Sympozjum EBHC. top
Partners
18th International EBHC Symposium 2023
Integrating evidence for enhanced outcomes
October 9-10, 2023 | hybrid format
18th International EBHC Symposium 2023
Integrating evidence for enhanced outcomes
October 9-10, 2023 | hybrid format
Piętak-Frączek
Magdalena Ankiersztejn-Bartczak, PhD in social sciences: pedagogue, sex educator, sociologist, certified educator, HIV/AIDS consultant and counsellor, President of the Management Board of the Social Education Foundation, member of the HIV/AIDS, viral Hepatitis and Tuberculosis Civil Society Forum at the European Commission, member of the International AIDS Society, the European AIDS Clinical Society and the Polish AIDS Society (PTnAIDS), co-author of the Polish Recommendations “Principles of care for people infected with HIV”, coordinator and advisor of the Consultation and Diagnosis Points and the Mobile Harm Reduction Service, author of numerous publications and educational programmes honoured with the Red Ribbon. top
Doctor of health sciences with a master’s degree in public health and economics. She is an author of numerous publications on cost effectiveness analysis, integrated care and quality of life. She has many years of teaching experience and she is the author of a unique model for educating students of Public Health in the field of pharmacoeconomics. Ewa Bandurska is the head of the Public Health – management in the health system faculty (first-cycle studies). Moreover, she is a member of the Polish Pharmacoeconomics Society (currently a member of the audit committee), the Polish Society for Health Programs, the Polish Society of Social Medicine and Public Health. She also holds the position of the supervisor of the Management and Economics in Health Care scientific club at the Medical University of Gdańsk and co-supervisor of the ISPOR Student Chapter Poland – a nationwide scientific club for pharmacoeconomics students. Furthermore, Ewa Bandurska cooperates with, among others, the National Institute of Public Health – National Institute of Hygiene, the Medicover Foundation, the World Bank and other entities. top
Lecture topic: Role of patient-reported outcomes in assessing the effectiveness of care on the example of integrated care
Michał Byliniak has been associated with the pharmaceutical market for over 15 years, acquiring extensive managerial experience in the field of distribution, reimbursement, clinical trials and registration of medicinal products. Michał Byliniak was a long-term president of the Regional Pharmaceutical Council in Warsaw, as well as the president of the Pharmaceutical Group of the European Union. Director General of the Employer’s Union of Innovative Pharmaceutical Companies INFARMA since 2022. He has experience in working in the Polish health care system, in various organisations, such as pharmacies, domestic wholesalers, pharmaceutical companies and consulting companies. He is the author of numerous studies related to the pharmaceutical sector. top
Lecture topic: HTA development from an industry perspective
Michał Chodorek - Attorney-at-Law, specialist in the field of Life Sciences law (including pharmaceutical law, medical devices) as well as intellectual property law and personal data protection in the Healthcare and Life Sciences industries. Michał also advises clients on manufacturing and distribution of medicinal products, e-Health and m-Health projects, conducting clinical trials, development of medical devices (including medical device software), obtaining and using medical data - including for training neural networks, data reuse from participants in clinical trials, development and implementation of AI / ML tools supporting diagnostic and therapeutic decisions.
He works for leading international pharmaceutical and medical companies operating in Poland and for many industry associations, including the INFARMA Employers' Union of Innovative Pharmaceutical Companies, an association of 25 most innovative pharmaceutical companies. Author of publications on the classification of software as a medical device, the use of AI in clinical trials and the process of research and development of drugs, processing of personal data in clinical trials, co-author of international publications on Digital Healthcare and protection of trade secrets. Michał Chodorek is a member of the Polish Association for Good Clinical Practice. It is recommended in the international legal ranking The Legal 500 EMEA 2022 in the field of Healthcare & life sciences and recognized as IP Star 2022 in the field of trademarks in the ranking on intellectual property law, conducted by Managing IP. top
Lecture topic: EU Health Data Space – secondary use of data from the patients' perspective
Grażyna Cieślak is a long-time coordinator of projects implemented in the area of health and health care, including the prevention of diabetes, colon and cervical cancer, as well as infrastructure projects introduced by public hospitals. She was responsible for administrative and financial aspects of various research and scientific projects, including “Evolvable platform for programmable nanoparticle-based cancer therapies (EVO-NANO) and “In-vivo Gene Editing by NanotransducErs (I-GENE)”. All her projects aim at determining the best value for patients. She is employed at the Gdańsk Centre for Health Promotion and Addiction Prevention and cooperates with the Polish Society for Health Programmes in Gdańsk. Grażyna Cieślak provides supervisory support to health care providers and institutions preparing and implementing health programmes. She is involved in actions advocating quality and effectiveness in the health care system, in particular in the area of lifestyle diseases. top
Lecture topic: Implementation and results of the prediabetes project – the patient’s perspective. How can this success be replicated?
Justin Clark is the Research Enhancement Manager at the Institute for Evidence-Based Healthcare (IEBH). He is also the Cochrane Information Specialist for the Acute Respiratory Infections Group, a member of the Cochrane Information Specialists Executive and the Co-Lead of the search group of the Living Evidence Network. He is one of the inventors of the Two-Week Systematic Review (2weekSR) method, a founding member of the International Collaboration for the Automation of Systematic Reviews (ICASR) and currently heads up the Automation Team at the IEBH. His work focuses on locating and retrieving information to minimise resources required to conduct reviews of the evidence, and he also develops tools and methods for the automation of systematic reviews. top
Lecture topic: Efficent HTA literature searching
Karen Facey worked as a statistician in pharma and medicines regulation, before becoming CEO of the first national HTA Agency in Scotland. For the past 20 years, she has worked as an international consultant in HTA, with special interests in use of real world data, evaluation of rare disease treatments and patient involvement. She is senior advisor for HTA at FIPRA, providing secretariat to the payer-led learning network, RWE4Decisions. top
Lecture topic: Collaboration to develop robust Real World Evidence for Decision Making
Clifford Goodman, PhD, is an independent consultant in health care technology and policy. Previously, he was Senior Vice President at The Lewin Group (an Optum company and subsidiary of UnitedHealth Group), a health care policy consulting firm where he served for 27 years. He has four decades of experience in such areas as health technology assessment, evidence-based health care, clinical practice guidelines, health economics, and studies pertaining to health care innovation, regulation, and payment. He has directed studies and projects for an international range of government agencies; pharmaceutical, biotechnology, and medical device companies; health care provider institutions; and professional, industry, and patient advocacy groups. His recent work has involved such areas as chronic disease, infectious disease, cancer, rare diseases, diagnostic testing, gene therapy, pharmacogenomics, personalized medicine, biosimilars, value frameworks, value-based contracting, social determinants of health, and applications of real-world data.
Dr. Goodman served as chair of the Medicare Evidence Development & Coverage Advisory Committee (MEDCAC, 2009-12) for the US Centers for Medicare and Medicaid Services (CMS). He served as president of the professional society, Health Technology Assessment international (HTAi, 2011-13), and is a Fellow of the American Institute for Medical and Biological Engineering. In 2022, he received the David Banta Distinguished Career Award in Health Technology Assessment from HTAi. He earned a PhD from The Wharton School of the University of Pennsylvania, a Master of Science from The Georgia Institute of Technology, and a Bachelor of Arts from Cornell University. top
Lecture topic: Integrating data into evidence for HTA. Where is our future?
Tomasz Hryniewiecki is cardiologist and specialist in internal medicine. He holds the position of Representative to the Minister of Health for the National Cardiovascular Disease Programme 2022-2032. National consultant for cardiology. Professor Hryniewiecki is professionally and academically associated with the Cardinal Stefan Wyszyński Institute of Cardiology – National Research Institute, where he has been head of the Heart Valve Defects Clinic for 12 years. He was Director of the Institute from 2015 to 2022, which he transformed into a National Research Institute with the highest scientific category A+ and initiated its major modernisation. In 2020, Professor Hryniewiecki started to prepare the National Cardiovascular Disease Programme for 2022-2032. At the same time, he has started work on a programme of comprehensive and coordinated cardiac care, the “National Cardiac Network”, which is designed to facilitate the patient’s journey from primary care to diagnosis and modern treatment in appropriate specialist healthcare facilities. He is the author of numerous scientific papers, textbooks, and the editor-in-chief of journals, as well as scientific director of congresses. He is a fellow of the Polish and European Society of Cardiology. top
Lecture topic: Cardiological network - two years of experience
Inna has graduated from School of Social Work of Kyiv-Mohyla Academy National University in 2007 and since then her career is developing in social and humanitarian spheres. From 2007 till 2012 Inna was working in the Policy and Advocacy Department of All-Ukrainian Network of People Living with HIV, combating for ARV-treatment availability for those who needed it. In 2012 Mrs Ivanenko became one of the founders of patients based organization CF “Patients of Ukraine” and in 2018 was elected as its Executive director. CF “Patients of Ukraine” is a unique organization, uniting 50 members, who are leaders of patients organizations from 23 disease areas. Organization is a strong advocate for treatment access, anti-corruption medical procurement reform and overall healthcare reform in Ukraine, representing interests of more than 1,5 million patients with severe diseases. During full-scale war in Ukraine CF “Patients of Ukraine” is among leaders who helps to overcome Ukrainian patients and healthcare system the consequences of russian invasion. top
Lecture topic: Health care in Poland from the perspective of Ukrainian refugees
Tadeusz Jędrzejczyk, Graduate of the Medical Faculty of the Medical Academy in Gdańsk (nowadays known as the Medical University of Gdańsk). Specialist in Public Health. He has a PhD in medical sciences and holds the position of assistant professor in the Department of Public Health and Social Medicine. Author of several dozen articles on public health concerning, in particular, the field of management and organisation of health care, economic aspects and epidemiology. Councilor of the City of Gdańsk (1994-1998) and chairman of the City Commission for Solving Alcohol Problems (1997-2001). Deputy Healthcare Director at the University Clinical Centre in Gdańsk (2010-2014), Deputy Director and then Director of the Pomeranian Branch of the National Health Fund (2008-2009 and then 2013/14); President of the National Health Fund between June 2014 and March 2016. Currently, he is the Director of the Health Department of the Pomeranian Voivodeship Marshal's Office. top
Polish local government official, physician and activist of the German minority in Poland since 2010 to 2020, Deputy Marshal of the Opolskie Voivodeship. In the years 1999-2002, he was the director of the Department of Health and Social Policy of the Marshal’s Office of the Opolskie Voivodeship. In 2002, he was transferred to the position of Deputy Director for Medical Matters of the Regional Health Fund in Opole, and then took up a similar position in the Opole branch of the National Health Fund. He was also active in his community, participating in consultations regarding changes in the state health policy and the antibiotic therapy rationalisation programme. He was politically involved in the activity of the German minority in Poland within the Social and Cultural Association of Germans of Opole Silesia. In 2017, together with other German Minority members, he co-founded the “Regionalna. Mniejszość z Większością” (Regional. Minority with the Majority) party; in 2018 he became its deputy chairman. He taught classes at physician courses, as well as classes at the Pharmacoeconomics, Marketing and Pharmaceutical Law College at the Warsaw University of Technology. Roman Jacek Kolek has published scientific papers in the field of public health and health care finance, cost analyses of expenditure on health services provided to the insured, as well as lectures for physicians as part of training sessions and courses in public health and health insurance. He co-organised numerous conferences in the field of health policy and financing of health services, including the British-Polish Healthcare Forum, Polish-Ukrainian Healthcare Forum and the Polish-German Health Forum. He authored and co-authored numerous publications in the field of public health and financing of health services.
In 2020, during the pandemic, he resigned from the position of Deputy Marshal of the Opolskie Voivodeship, returned to the profession of an anesthesiologist, currently he is the Deputy Director of the Provincial Hospital for healthcare, he is the Quality Representative. top
National Consultant in the field of haematology. Vice-president of the Polish Adult Leukaemia Group. Member of the Polish Lymphoma Research Group.
Professor Ewa Lech-Marańda specialises in internal diseases, haematology, clinical transplantology and clinical immunology. She is the author of over 130 original works, review works and textbook chapters. In the years 1995-2010 she was an assistant and adjunct at the Department of Haematology of the Medical University of Łódź. In 2010, she started working at the Institute of Haematology and Transfusion Medicine in Warsaw as the deputy head of the Haematology Clinic. In the years 2015-2017, she served as the deputy Director for Therapeutics at the Institute, and in 2017 she was appointed by the Minister of Health as the Director of the Institute of Haematology and Transfusion Medicine. Since 2013, she has also been the head of the Haematology and Transfusion Medicine Clinic at the Centre of Postgraduate Medical Education in Warsaw and the voivodeship consultant in the field of haematology for the Masovian Voivodeship; what is more, since 2018, she has been working as the national consultant in the field of haematology. top
Lecture topic: Improving hematology patient care - hematology network in Poland
Head of Medical Training and Simulation Centre, University of Warmia and Mazury in Olsztyn, vice-President of The Polish Society for Medical Communication, healthcare expert of the Jagiellonian Club Analytical Centre, President of Polish Prader–Willi Syndrome Association. Member of the Expert Board to the Patients Ombudsman. top
Lecture topic: Patient in the world of digitasation
Manager, graduated from the Warsaw School of Economics (SGH), as well as from the MBA studies at the Leon Kozminski Academy of Entrepreneurship and Management in Warsaw – Management and Economics of Medical Technologies. His first professional experience was in investment banking at Polski Bank Inwestycyjny (Polish Investment Bank). Since the beginning, i.e. since April 1998, Maciej Miłkowski was co-organising Mazowiecka Regionalna Kasa Chorych (the Mazovian Regional Health Care Fund) and became its first member of the management board for economic and administrative affairs, as well as its CFO. For 3 years, starting from 2002, he was head of a non-public health care institution of the European Rehabilitation Clinic VICTORIA. In the years 2005-2007 he worked in the Institute of Mother and Child as the representative of the director for financial and accounting affairs and as the deputy director for economic affairs. Between June 2007 and January 2016 Maciej Miłkowski worked as the deputy director for economic affairs of the Cardinal Stefan Wyszyński Institute of Cardiology in Warsaw. In 15 January 2016 he was appointed the Deputy President of the National Health Fund for Financial Affairs. He has been the Under-Secretary of State at the Ministry of Health since 2018. top
Lecture topic: Formy opieki zdrowotnej dla uchodźców. Dane liczbowe i fakty nt. opieki zdrowotnej dla uchodźców w wybranych schorzeniach, w tym HCV i HI
Magdalena Ruth Moshi, BHlthSc (Hons), PhD, OLY
Dr Magdalena Ruth Moshi is a Senior Research Officer (SRO) at the Royal Australasian College of Surgeons (RACS). Her current role includes conducting health technology assessments as part of the Australian Safety and Efficacy Register of New Interventional Procedures-Surgical (ASERNIP- S) team.
Magdalena’s research interests include developing health technology assessment methodologies that can address the unique challenges posed by innovative software or healthcare contexts. She has peer reviewed articles on the topic for the International Journal of Technology Assessment in Health Care. top
Lecture topic:
HTA framework for digital technologies. Australian healthcare perspective
Graduate of the Faculty of Law and Administration at the University of Warsaw, specializing in digital policies within European Union law. Analyst of Polish, EU and US regulations related to new technologies, primarily data governance in various sectors (mainly healthcare). She has gained practical experience in Polish and international law firms, as well as in policymaking in the United Nations and Polish public administration initiatives. At the end of July, she finished traineeship at DG SANTE in the European Commission, where she supported work on the European Health Data Space. Currently she is a legal researcher in the Center of IT and IP Law in the KU Leuven, where she works on a Data Spaces Support Centre project. She is also a journalist writing texts on new technologies, as well as digital & energy policy in the CEE region. top
Lecture topic: European Health Data Space - digital future of healthcare?
Dan Ollendorf is Director of Value Measurement and Global Health Initiatives at the Center for the Evaluation of Value and Risk in Health (CEVR). His research interests include expanding the use of health technology assessment in low- and middle-income economies, as well as refinement of value assessment tools in the US. Prior to joining CEVR, Dr. Ollendorf was Chief Scientific Officer for the Institute for Clinical and Economic Review (ICER) for over 10 years, where he was responsible for scientific oversight of all clinical and economic aspects of the health technology assessment process.
Dr. Ollendorf holds a PhD in clinical epidemiology from the University of Amsterdam and an MPH from Boston University. He is the current Chair of the Health Technology Assessment International Global Policy Forum as well as a non-resident Fellow at the Center for Global Development, and served on the US Medicare Evidence Development and Coverage Advisory Committee (MEDCAC) from 2015-2019. Dr. Ollendorf has authored over 100 articles in peer-review journals and is co-author of The Right Price: A Value-Based Prescription for Drug Costs (Oxford University Press). top
Lecture topic: Charting a clear course : the road ahead for HTA
Wija Oortwijn jest starszym badaczem/wykładowcą na Wydziale Dowodów Zdrowotnych w Centrum Medycznym Uniwersytetu Radboud w Nijmegen (Holandia). Studiowała nauki o zdrowiu i uzyskała tytuł doktora nauk medycznych (ustalanie priorytetów w ocenie technologii medycznych). Ma ponad 30-letnie doświadczenie zawodowe w HTA i analizie polityki zdrowotnej na całym świecie, a jej głównym zainteresowaniem jest ustalanie priorytetów, zintegrowane HTA i budowanie potencjału.
Od 1992 roku jest szczególnie zaangażowana w rozwój HTA i wzmacnianie systemów opieki zdrowotnej na całym świecie. Obejmuje to liczne projekty, konsultacje i budowanie potencjału w większości krajów Unii Europejskiej, a także w Abu Zabi, Brazylii, Kanadzie, Chinach, Kazachstanie, Mołdawii, RPA, Ukrainie i wielu innych państwach.
Jest współautorką 10 rozdziałów książki dotyczących różnych aspektów HTA, redaktorką kilku numerów czasopism i autorką ponad 70 innych publikacji naukowych. Jest głównym redaktorem the VALIDATE handbook: an approach on the integration of values in doing assessments of health technologies, 2022; dostępnej na: https://validatehta.eu/. Jest także główną autorką wytycznych dotyczących instytucjonalizacji HTA poprzez wykorzystanie procesów deliberacyjnych opartych na dowodach, 2021; dostępność: https://www.radboudumc.nl/global-health-priorities. Wytyczne te są stosowane w kilku krajach na całym świecie, w tym w Abu Zabi, Ghanie, Iranie, Indonezji, Kazachstanie, Kirgistanie, Libanie, Liberii, Mołdawii, Pakistanie, Rwandzie, Tanzanii i na Ukrainie.
Jest członkiem-założycielem Holenderskiego Towarzystwa HTA (NVTAG) i Międzynarodowego Towarzystwa HTA (HTAi). W latach 2011-2017 była współprzewodniczącą grupy zainteresowań HTAi/INAHTA ds. etyki, a w latach 2016-2019 pełniła funkcję sekretarza naukowego Global Policy Forum HTAi.
Obecnie jest członkiem zarządu HTAi w charakterze byłego Prezesa, jest współprzewodniczącą grupy roboczej HTAi-DIA ds. niepewności na interfejsie regulacyjnym HTA i jest współredaktorem International Journal of Technology Assessment in Health Care. Jest również członkiem Rady Doradczej słowackiej agencji HTA (NIHO) oraz grupy roboczej HTAi-ISPOR-HTAsiaLink ds. wytycznych HTA. top
Lecture topic: Integrated health technology assessment for
evaluating complex technologies
Mark Parker is director at ZEM Solutions with more than 20 years experience in international health economics projects and health technology assessment. He is Health Economic modeller (University of Liverpool, University of York, UK) and Health Economics Consultant. Primarily involved in leading the development of care pathways, economic models and their evidence basis for use in global value dossiers, international HTA submissions, and national projects such as DRG development, patient registries and their analysis. Further specialising in the challenges of the CEE region and healthcare development. Mark has experience in a wide range of disease areas and population modelling, he is working with industry, NGOs and governmental institutions to deliver a strong educational background in economics, software development, distributed systems and computation, Artificial Intelligence (1st, BSc Economics and Computer Science, UoL).
top
Lecture topic: Turning Real World Data into Real World Evidence with Health Economic Modeling
Associate Professor Bonny Parkinson is the Interim Deputy Director and a health economist at the Macquarie University Centre for the Health Economy (2022). She has also worked at the University of Technology Sydney, AstraZeneca in the United Kingdom, Access Economics, and the Australian National University. She currently co-leads a team of researchers conducting evaluations of submissions to the Pharmaceutical Benefits Advisory Committee (PBAC) and researching economic evaluation methodology. She has been involved in over 50 evaluations of submissions to the PBAC since 2009, and has also conducted evaluations of submissions to the Medical Services Advisory Committee (MSAC). To date, she has been the recipient of career research funding of over $22.0 million spread over 16 grants and has 38 peer-reviewed journal articles. She is currently on the editorial board of Pharmacoeconomics, and is an associate editor of Oxford Open Economics. top
Lecture topic: Uncertainty in HTA
Specialist in internal medicine, haematology and immunology. Professor and lecturer at the Faculty of Medicine and Health Science of Jan Kochanowski University in Kielce. Since 2015, he has held the position of the Voivodship Consultant in Haematology. He graduated from the Medical University of Lublin (where he also obtained his doctorate in medical sciences in 2009). Since 2001, he has been working at the Holy Cross Cancer Centre in Kielce. Since 2011, he has been in charge of the haematology unit and, since 2014, of the Department of Haematology and Bone Marrow Transplantation at the Holy Cross Cancer Centre. Scientific research on the assessment of the effectiveness of vaccination against Streptococcus pneumoniae (pneumonia ducta) in patients with chronic lymphocytic leukaemia and monoclonal gammopathy of undetermined significance has been carried out under the supervision of Professor Pasiarski. Based on his research, he developed the first pneumococcal vaccination programme in Poland and Europe for oncological patients, offering them protection against pneumococcal pneumonia and sepsis. top
Lecture topic: Pneumoccocal infection prevention programme for adults. Risk group: cancer patients
Serhii Pekh | Ukraine | 2023
Serhii Pekh is a unique influencer whose activities on social media have meaningful impact on society. His main goal is to make the rules of legal residence in Poland and procedures for entering Poland more commonly known, not only for Ukrainian citizens, but also for other nationalities. As a community activist, Serhii is a co-founder of Wellcome EU foundation, which aims to help refugees from various countries in difficult times. Serhii Pekh is not only an influencer, but also a philanthropist. His involvement in helping refugees of various nationalities shows that he always puts humanitarian matters first. Moreover, as an investor, he’s aware of the role that business can play in creating positive social changes. His versatility and psychological knowledge help him understand how social media works and what is the best way of conveying his social messages. Serhii Pekh is an individual who inspires and motivates others to work for the common good and understands the needs of refugees and migrants in Poland, regardless of their country of origin. top
Prezes Fundacji Gwiazda Nadziei. Lider Koalicji Hepatologicznej. Działaczka na rzecz pacjentów cierpiących na choroby wątroby. Była pacjentka wyleczona z WZW C. Od ponad 15 lat współzałożycielka i prezes Fundacji Gwiazda Nadziei.
Zawodowo od ponad 25 lat związana jest z samorządem terytorialnym, aktualnie z samorządem województwa. Radna Powiatu Mikołowskiego V Kadencji, aktualnie Przewodnicząca Rady Powiatu Mikołowskiego VI Kadencji. Inicjatorka licznych akcji społecznych, szkoleń oraz programów edukacyjnych z zakresu profilaktyki chorób wątroby oraz chorób nowotworowych. Współtwórca licznych kampanii edukacyjnych skierowanych do młodzieży, nauczycieli, mieszkańców, lekarzy a w ostatnim czasie również do uchodźców z Ukrainy. Pomysłodawczyni, współautor oraz koordynator wydawanych przez Fundację Gwiazda Nadziei publikacji wykorzystywanych w kampaniach promujących akcje bezpłatnych badań oraz edukujących lekarzy rodzinnych i nauczycieli z zakresu aktualnej wiedzy o zakażeniach wirusami hepatotropowymi.
W życiu wyznaje dewizę, że zdrowie i życie ludzkie są wartością nadrzędną. top
She has been working at the Cracow City Hall for 20 years, since 1999. She graduated from the Nursing Institute at the Faculty of Healthcare of the Jagiellonian University Medical College. In 1997, she completed post-graduate studies in Health Promotion at the Institute of Public Health of the Jagiellonian University. In 2012, she completed post-graduate studies in Economy and Public Administration at the Małopolska School of Public Administration of the Cracow University of Economics. In 2019, she completed post-graduate studies in HTA and EBM in Healthcare Management as part of the “Development of administrative and management competences for quality improvement in healthcare” project organised by the Faculty of Health Sciences of the Jagiellonian University. From the beginning of her work, she has been developing the principles of the “Healthy Cracow” Municipal Healthcare Programme, organising conferences, trainings and outdoor health-related events, including the “Cracow Health Days”. She cooperates with numerous regional and national healthcare-related institutions. She is also a representative of the City of Cracow in the Association of Healthy Polish Cities and the President of the Management Board of the Association. As part of this activity, among others, she organises meetings for member cities which address significant issues regarding healthcare and prevention. Healthcare manager - completed postgraduate studies in 2022: Healthcare management. top
Robert Plisko is CEO at HTA Consulting since 2006 and one of the company’s founders. He obtained his Master of Economics title at the Cracow University of Economics. His professional career started at the National Centre for Quality Assessment in Healthcare. Robert Plisko is the author of numerous publications on HTA and health care. He is head of the Economic Analyses Department at HTA Consulting. top
Managing Director of CEESTAHC. Graduate of the Faculty of Medicine of the Medical University in Łódź and Postgraduate Health Care Management Studies in the Nofer Institute of Occupational Medicine. Expert in cooperation and creation of health projects with local government units, with many years of experience in creating an educational platform for developing high-quality health programmes in important areas of public health. President of the European Foundation for Solving Health Problems (Europejska Fundacja Rozwiązywania Problemów Zdrowotnych). Co-creator of the “Zdrowie/Człowiek/Profilaktyka” educational programme, aimed at local governments and employers. Initiator of www.dobreprogramyzdrowotne.pl, a website containing a Health Programme Creator and educational materials for creators of health policy programmes. top
Michael Schlander is Professor of Health Economics (at AWI – Alfred Weber Institute for Economics and at the Mannheim Medical Faculty) of the University of Heidelberg, currently on leave of absence to act as foundation Head of the Division of Health Economics for the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ), Heidelberg, Germany (since 2017). He has been founding chairman of the not-for-profit “Institute for Innovation & Valuation in Health Care” (InnoValHC e.V.) in Wiesbaden, Germany (since 2005), and has acted a scientific advisor of its consulting and management branch, Inno-Val-HC-Forschungsgesellschaft mbH (InnoValHC Research Inc., also since 2005). He is a member of numerous scientific associations, including the Drug Information Association (DIA), the International Health Economics Association (iHEA), and the International Society for Pharmacoeconomics and Outcomes Research (ISPOR); in 2008, he was a co-founder of the German Society for Health Economics (Deutsche Gesellschaft für Gesundheitsökonomie, DGGÖ). He further acted as the scientific program chair for the 15th Annual European Congress of ISPOR in 2012, with more than 3,500 attendants. After six years in experimental brain research and clinical neurology (at the Universities of Frankfurt a.M. and Mainz), he joined the international biopharmaceutical industry in 1987, where he spent 15 years in executive roles in clinical development (1987-1993), marketing (1993-1999), and general management (1999-2002) in Belgium, Germany, Switzerland, and the United States. His scientific publications include two monographs, on ‘The Contribution of Health Economics to Market-Oriented Pharmaceutical Research and Development’ (Witten/Herdecke University Press; Witten, Germany: 1998) and on ‘Health Technology Assessments by the National Institute for Health and Clinical Excellence (NICE)’ in England and Wales (Springer; New York, NY: 2007). top
Lecture topic: Changing perspectives on value
President of EconMed Europe, graduate of CMUJ, specialist in public health and epidemiology, Doctor of Economics in the field of health economics. He specialises in health economics, HTA and drug management. An expert at the European Commission (evaluating grants in the HORIZON programme), long-time lecturer of HTA and health economics – assistant professor at Collegium Medicum of the Jagiellonian University (2009-2016). In the past, he served as the Lesser Poland Provincial Sanitary Inspector and the Head of the Department of Drug Administration of the Lesser Poland Provincial Branch of the National Health Fund. Michał Seweryn is the author of scientific publications and specialised studies in the field of health economics and epidemiology. top
Lecture topic: Ścieżki finansowania szczepień dla dorosłych – na przykładzie półpaśca (wykład edukacyjny firmy GSK)
Sociologist – HTA expert – with more than 20 years of professional experience in public and private institutions related to health technology assessment (HTA/EBM), total quality management (TQM), clinical indicators, quality of life assessment, health insurance, and clinical research. He has held management positions in the CEESTAHC Association, WHC and Medicea Foundations, clinical research centres and numerous companies involved in broadly defined quality, ancillary insurance, and HTA. He currently holds the position of Director at the AOTMiT’s Branch Office in Cracow. He was the initiator and organiser of the International EBHC Symposium (2004-11) of the CEESTAHC Association, and of the conference series entitled “Innovations in Medicine” of the WHC Foundation. Jacek Siwiec is a manager, organiser, coach in trainings and several hundred training programmes in the field of EBM/EBHC/HTA/GCP, and an academic lecturer – at i.a. postgraduate studies in HTA at Institute of Public Health at Jagiellonian University Medical College (PRO-QUO HEALTH, HB-HTA). He has held advisory roles as, i.a., a member of the Ministry of Health’s Team for the Translation of Maps of Healthcare Needs, expert of the AOTMiT’s Tariffs Council, HTA coordinator of the Pointer project. Additionally, he is a member of teams and co-author of the Minister of Health’s “IOWISZ” tool. Jacek Siwiec is the co-author of HTA studies and expert consultations for Ministries of Health of the following Serbia (on behalf of the World Bank) and Ukraine. He has cooperated with various international institutions such as WHO (HEN), EUnetHTA, HTAi, World Bank and DG SANCO – member of the Expert Group on Health Systems Performance Assessment (HSPA), as well as Polish and foreign universities. Currently, he participates in several task forces and consulting teams, such as Voivodship Health Needs Mapping Teams, or in the work of the President of the Republic of Poland’s Working Group on 75 + Centres, as well as in the work of the Steering Committee for the Coordination of EFSI Interventions in the Health Sector. He has been an expert member, Polish representative for HTA methodology to the EU team – Coordination Group on Health Technology Assessment (CG-HTA), dealing with the commonality of HTA activities in the EU, since 2023. top
Head of the Department and Clinic of Infectious Diseases and Hepatology of Medical University of Lublin. A long-time member of the board of the Polish Association for Study of Liver (PASL), vice-president of the Polish Society of Epidemiology and Infectious Diseases Physicians (PTEiLChZ). Founding member of CEHC. Head of numerous projects of national and international research. Principal researcher in over 20 clinical trials in the field of infectious diseases and hepatology. Chairman of the Polish NAFLD/NASH Expert Group, Chairman of the Polish HCV Expert Group, Member of the Polish HBV Expert Group, Member of the Expert Group for Combating Healthcare-Associated Infections. Former member of the National COVID-19 Medical Council. Reviewer of the European Association for the Study of Liver Disease (EASL) International Liver Congress for the years 2019-2021. Expert on the HCV elimination at the invitation of the World Health Organisation (WHO. Co-author of the national recommendations for the management and treatment of HCV, HBV, NAFLD/NASH and ricketsioses. Frequent reviewer of therapeutic programs for the Agency for Health Technology Assessment and Tariff System, as well as research projects for the National Science Centre (NCN). Member of the Scientific Committee of joint project "International Transfer of Health Data" The European Federation of Academies of Sciences and Humanities (ALLEA), the European Academies' Science Advisory Council (EASAC) and Federation of European Academies of Medicine (FEAM). In recent years, very close cooperation with the Department of Gastroenterology and Hepatology, Essen University Hospital in Essen (Germany) and the Department of Gastroenterology, Hepatology and Endocrinology, Medical School Hannover (Germany). Krzysztof Tomasiewicz is the author of numerous original and review works of total IF of over 350 and a number of citations of over 6000, h-index 23. Editor-in-Chief of “Clinical and Experimental Hepatology”, Guest Editor in the field of Gastroenterology of the Frontiers publishing house. top
Lecture topic: Prevention of infectious diseases as a challenge by 2030 on the example of HCV
Prezes Stowarzyszenia CEESTAHC. Wiceprezes firmy HTA Consulting, w której odpowiedzialna jest za strategiczny rozwój firmy. Jej głównym celem jest zapewnienie wysokiej jakości informacji i danych w oparciu o EBM i HTA. Podejmuje działania nie tylko na terenie Polski, ale także w Europie i Azji. Jej kluczowym zadaniem jest poprawa wyników leczenia pacjentów poprzez podejmowanie lepszych decyzji leczniczych.
W CEESTAHC jest odpowiedzialna za przygotowanie i zapewnienie platformy do dyskusji dla wszystkich zainteresowanych grup interesów w sektorze opieki zdrowotnej. Misją CEESTAHC jest poprawa jakości opieki zdrowotnej w oparciu o dowody.
Jest absolwentką Akademii Medycznej w Lublinie oraz Ekonomii i MBA na Akademii Leona Koźmińskiego w Warszawie.
W latach 2006-2008 była członkiem corocznych spotkań HTAi. top
Tematy wykładów: JCA – wspólna ocena kliniczna and Cancer care coordination - experiences of patients in Poland
Marek Wójcik, healthcare expert at the Association of Polish Cities, Deputy Minister of Administration and Digitisation in the years 2014-2015, long-term participant of legislative works in the Polish Sejm and Senate; member of the health and social policy team of the Joint Commission of the Government and Local Governments and participant in the work of the Council for Social Dialogue. Since 2004, he has served three terms as chairman of the Council of the Małopolskie Regional Branch of the National Health Fund, an expert to the Minister of Health for restructuring healthcare facilities and ownership transformations (2009-2011), member of the Council for Public Health and of the Scientific Council of the National Influenza Control Programme. He supervises the activities of medical entities subordinate to the Sądecka Municipal Public Services Zone (pilot project), and the Nowy Sącz poviat. Author of publications on public health and health programmes created by local governments. In his didactic activity, he collaborates i.a. with the Cracow University of Economics, Lazarski University in Warsaw, Warsaw School of Economics, Medical University of Łódź, WSB – National Louis University in Nowy Sącz, and University of Business and Entrepreneurship in Ostrowiec Świętokrzyski. top
Economist and social entrepreneur interested in complex systems, political economy of technology and digital economy. Co-President of the Polish Network of Economics and Program Director at CoopTech Hub, first Polish center for platform co-ops. PhD candidate at Kozminski University and lecturer at Management and AI in Digital Society program. Founder and 2015-2020 Chairman of the Board at Instrat, a progressive policy think-tank. He gained experience i.a. in the Polish Development Fund. Graduate of the Warsaw School of Economics, fellow of G20 Global Solutions, British Council, Møller Institute, Open Future Foundation & FEPS. Author of “Network Capitalism” (“Kapitalizm Sieci”), nominated to “Economicus 2020” prize. DigitalEU Ambassador. top
Lecture topic: EHDS – the digital future of medicine
English (UK) 
Polski